Fol. Biol. 2012, 58, 246-250
https://doi.org/10.14712/fb2012058060246
Methylation Analysis of Tumour Suppressor Genes in Ovarian Cancer Using MS-MLPA
References
1. , R., Hyde, C. A., Zhong, X. Y. (2010) Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol. Oncol. 118, 81-87.
<https://doi.org/10.1016/j.ygyno.2010.03.015>
2. , G. M., Suijkerbuijk, K. P., Bart, J., Vooijs, M., van der Wall, E., van Diest, P. J. (2010) Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology 57, 363-370.
<https://doi.org/10.1111/j.1365-2559.2010.03642.x>
3. , V. F., Nancarrow, D. J., Stark, M. S., Moser, R. J., Boyle, G. M., Aoude, L. G., Schmidt, C., Hayward, N. K. (2011) Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. PLoS One 6, e26121.
<https://doi.org/10.1371/journal.pone.0026121>
4. , K. Y., Ozçelik, H., Cheung, A. N., Ngan, H. Y., Khoo, U. S. (2002) Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res. 62, 4151-4156.
5. , M., Palička, V. (2011) The most frequent methods used for DNA methylation analysis. Cas. Lek. Cesk. 150, 442-445. (in Czech)
6. , W., Marquez, R. T., Lu, Z., Liu, J., Lu, K. H., Issa, J. P., Fishman, D. M., Yu, Y., Bast Jr. R. C. (2008) Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112, 1489-1502.
<https://doi.org/10.1002/cncr.23323>
7. , E., Catasus, L., Argüelles, R., Moreno-Bueno, G., Palacios, J., Gamallo, C., Matias-Guiu, X., Prat, J. (2001) Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 92, 2829-2836.
<https://doi.org/10.1002/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO;2-3>
8. , M. M., Campan, M., Figueroa, J. D., Yang, X. R., Lissowska, J., Peplonska, B., Brinton, L. A., Rimm, D. L., Laird, P. W., Garcia-Closas, M., Sherman, M. E. (2009) DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations. Cancer Epidemiol. Biomarkers Prev. 18, 3036-3043.
<https://doi.org/10.1158/1055-9965.EPI-09-0678>
9. , I., Battagli, C., Esteller, M., Herman, J. G., Dulaimi, E., Edelson, M. I., Bergman, C., Ehya, H., Eisenberg, B. L., Cairns, P. (2004) Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 64, 6476-6481.
<https://doi.org/10.1158/0008-5472.CAN-04-1529>
10. , P. A., Baylin, S. B. (2007) The epigenomics of cancer. Cell 128, 683-692.
<https://doi.org/10.1016/j.cell.2007.01.029>
11. , M., Sasaki, M., Tanaka, Y., Shiina, H., Yamada, H., Yamamoto, R., Sakuragi, N., Enokida, H., Verma, M., Dahiya, R. (2005) WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 104, 1924-1930.
<https://doi.org/10.1002/cncr.21397>
12. B. Y. (2009) Patients at high risk for ovarian cancer should undergo routine screening. Clinical Ovarian Cancer 5, 83-89.
<https://doi.org/10.3816/COC.2009.n.015>
13. , F. C., Young, T. W., Liu, J., Cheng, X. (2006) RASmediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FASEB J. 20, 497-499.
<https://doi.org/10.1096/fj.05-4586fje>
14. , C. B., Verschuur-Maes, A. H., van Diest, P. J. (2011) Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J. Pathol. 225, 222-231.
<https://doi.org/10.1002/path.2930>
15. , C., Gloss, B. S., Warton, K., Barton, C. A., Statham, A. L., Scurry, J. P., Tabor, B., Nguyen, T. V., Qu, W., Samimi, G., Hacker, N. F., Sutherland, R. L., Clark, S. J., O’Brien, P. M. (2012) Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol. Oncol. 124, 582-888.
<https://doi.org/10.1016/j.ygyno.2011.11.026>
16. , A. O., Ameziane, N., Duarte, H. M., Vijzelaar, R. N., Waisfisz, Q., Hess, C. J., Schouten, J. P., Errami, A. (2005) Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 33, e128.
<https://doi.org/10.1093/nar/gni127>
17. , W. A., Crume, K. P., Grimes, M. J., Winters, S. A., Toyota, M., Esteller, M., Joste, N., Baylin, S. B., Belinsky, S. A. (2003) Aberrant promoter methylation of the transcription factor genes PAX5 a and b in human cancers. Cancer Res. 63, 4620-4625.
18. , H. J., Suh, D. S., Choi, K. U., Yoo, H. J., Joo, W. D., Yoon, M. S. (2011) Inactivation of O6-methyguanine-DNA methyltransferase by promoter hypermethylation: association of epithelial ovarian carcinogenesis in specific histological types. J. Obstet. Gynaecol. Res. 37, 851-860.
<https://doi.org/10.1111/j.1447-0756.2010.01452.x>
19. Tavassoli, F. A, Devilee, P. (eds.) (2003) World Health Organization. Classification of Tumors. Pathology and genetics: tumors of the breast and female genital organs. pp. 113-202. IARC Press, Lyon.
20. , I. J., Niessen, H. E., Derks, S., Baldewijns, M. M., van Criekinge, W., Herman, J. G., van Engeland, M. (2011) Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin. Cancer Res. 17, 4225-4231.
21. , K., Akiyama, Y., Aso, T., Yuasa, Y. (2006) Involvement of GATA-4/-5 transcription factors in ovarian carcinogenesis. Cancer Lett. 241, 281-288.
<https://doi.org/10.1016/j.canlet.2005.10.039>
22. , J. H., Dammann, R., Pfeifer, G. P. (2001) Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int. J. Cancer 94, 212-217.
<https://doi.org/10.1002/ijc.1466>
